CVS Health Corp

CVS Health is a diversified healthcare services company with leading positions in pharmacy benefits management, retail pharmacy, and health insurance via its Aetna franchise. The company reported strong first-quarter results, raised full-year guidance, and saw S&P revise its credit outlook from negative to stable. This positive momentum is supported by improving industry fundamentals and company-specific execution, indicating a potential for long-term shareholder value. The recent changes in management and strategy are expected to enhance returns on invested capital and strengthen the company's market position.

CVS Health is a diversified healthcare services company with leading positions in pharmacy benefits management, retail pharmacy, and health insurance via its Aetna franchise. We initiated our investment in early 2025 after shares had fallen, driven largely by prior management's 'growth at any cost' strategy in Medicare Advantage. During the second quarter, CVS benefited from both company-specific execution and improving industry fundamentals. The company reported strong first-quarter results, raised full-year guidance, and saw S&P revise its credit outlook from negative to stable.

CVS Health has shown resilience in its pharmacy benefit manager operations and has benefited from moderating medical cost trends and continued retail pharmacy growth. The market is beginning to price in the likelihood of longer-term profit growth for CVS Health, which has been a significant contributor to our portfolio's performance. We believe that the company's strong position in the health care sector will continue to yield positive results.

We have seen strong stock selection in Health Care, particularly with CVS Health, which has contributed positively to the Fund's relative results. The company is well-positioned within the sector, and we believe its fundamentals support our investment thesis. Our confidence in CVS Health is reflected in our decision to increase our position during the quarter, as we see compelling opportunities for growth and value creation in the long term.

CVS Health has shown strong performance, with first-quarter earnings exceeding expectations and full-year guidance being raised. This has bolstered confidence in the company's turnaround strategy. Additionally, the reduction in policy uncertainty surrounding exchange subsidies has further supported CVS Health's positive outlook. The overall sentiment towards managed care has improved, contributing to CVS's rise in the market.

CVS Health is on track toward recovery in its Medicare Advantage insurance book, which is a positive indicator for the company's future performance. Despite facing regulatory headwinds in the health care sector, the outlook for CVS Health appears to be improving, suggesting that it may capitalize on the recovery in this segment. The manager's confidence in CVS Health's recovery is a key reason for the bullish stance.

CVS Health Corp is mentioned as a holding in the portfolio, but there is no explicit directional argument made about its future performance or valuation. The letter discusses the overall performance of the health care sector and mentions CVS Health Corp in the context of portfolio characteristics without providing a specific investment thesis.

CVS Health Corporation outperformed in the period, driven by solid quarterly earnings results and better-than-expected 2025 guidance. The preliminary 2026 Medicare Advantage Rate Notice proposes a meaningful increase for Medicare Advantage payments, which is expected to enhance CVS's positioning in this area. Management is focused on improving margins and enhancing its business in Medicare Advantage, believing it can remain an attractive business for Aetna and CVS Health over time. The company is also taking actions to drive long-term success, including leadership appointments aimed at turnaround efforts.

CVS Health has rebounded strongly after weak 2024 performance, up over 50% in the first quarter. The company faced challenges in 2024 due to weaker sales at its pharmacies and higher medical costs in its Medicare Advantage health insurance segment. However, the results rebounded in the fourth quarter under new CEO David Joyner, who joined in October. The strong results fueled investor hopes for a turnaround. Consistent with our contrarian approach, we added to CVS during 2024 and early 2025 to take advantage of the company’s depressed valuation and our positive long-term outlook for the company.

CVS Health was a top contributor. The stock rallied on the perceived benefit to its managed care segment following an announcement by the Centers for Medicare and Medicaid Services of a proposed 4.3% average increase in government payments to Medicare Advantage plans in 2026. CVS also beat both revenue and earnings expectations for the fourth quarter, supporting hopes for a turnaround in its Aetna insurance segment and stabilizing profits in its pharmacy operations.